CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the ...

CSL Ltd. plunged the most on record after the Australian biotechnology company cut its full-year outlook and flagged about $5 ...

The global biotechnology company will brief analysts on its latest downgrade on Monday morning after a horror year for the ...

Recent CSL Ltd (ASX: CSL) results disappointed, leading to short-term pressure on the share price. However, certain quality ...

CSL now expects weaker full-year revenue and profit as plasma, China pricing, and Vifor pressures weigh on performance.

- Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring's portfolio KING OF ...

The Pennsylvania biotech company CSL Behring says it is on track to file for approval of its hemophilia B gene therapy by the end of June after releasing pivotal data showing statistical superiority ...

SYDNEY--Pharmaceutical company CSL on Monday downgraded its annual earnings guidance and signaled another $5 billion of pretax impairments, including for the Vifor business that it acquired for $11.7 ...

The broker has been looking over the biotech giant's guidance downgrade. The post 'Blood on the Street': What is Bell Potter saying about the CSL share price crash? appeared first on The Motley Fool ...

Moscow opening reinforces CSL Behring's promise to deliver its world-class therapies to patients with rare and serious diseases around the world. KING OF PRUSSIA, Pa. — 08 December 2015 - Global ...